AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01558310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
Study NCT01558310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
Study NCT01558310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
Study NCT01558310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
Study NCT03089125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyspnea Intervention
Description: Dyspnea intervention will be administered over two sessions~Patients will receive:~* Psychoeducation~* Relaxation training for reducing physiological stress~* Behavioral techniques for managing acute breathlessness
Study NCT03089125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians
Study NCT03089125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians
Study NCT02424084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy
Study NCT00998400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT in combination with WBT and life style modification
Description: CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems. The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others. CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
Study NCT01329354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous effector lymphocytes expanded ex-vivo
Description: Maintenance therapy with Rituximab every two months is the standard of care for patients with follicular lymphoma after induction therapy. The intervention consists on the administration of autologous effector lymphocytes expanded ex-vivo every two Rituximab administrations.
Study NCT01772784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phenolic acids
Description: Phenolic acids
Study NCT01772784 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phenolic acids
Description: Phenolic acids
Study NCT01772784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phenolic acids
Description: Phenolic acids
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: This intervention is provided as tablet containing 150 mg of tafenoquine. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched-Placebo for Tafenoquine
Description: This intervention contains tafenoquine matched-placebo. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched-Placebo for Tafenoquine
Description: This intervention contains tafenoquine matched-placebo. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: This intervention is provided as over-encapsulated tablet containing 15 mg of primaquine. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched-Placebo for Primaquine
Description: This intervention contains primaquine matched-placebo. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matched-Placebo for Primaquine
Description: This intervention contains primaquine matched-placebo. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHA-PQP)
Description: This formulation is provided as tablet containing 320 mg of piperaquine tetrasphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). This tablet will be administered orally as single dose for 3 days. For subjects weighing \<75 kg, 3 tablets will be administered per day. For subjects weighing >=75 kg, 4 tablets will be administered per day. Dose will be taken at least 3 hours after last food intake. No food will be allowed for at least 3 hours after dosing.
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHA-PQP)
Description: This formulation is provided as tablet containing 320 mg of piperaquine tetrasphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). This tablet will be administered orally as single dose for 3 days. For subjects weighing \<75 kg, 3 tablets will be administered per day. For subjects weighing >=75 kg, 4 tablets will be administered per day. Dose will be taken at least 3 hours after last food intake. No food will be allowed for at least 3 hours after dosing.
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQP)
Description: This formulation is provided as tablet containing 320 mg of piperaquine tetrasphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). This tablet will be administered orally as single dose for 3 days. For subjects weighing \<75 kg, 3 tablets will be administered per day. For subjects weighing >=75 kg, 4 tablets will be administered per day. Dose will be taken at least 3 hours after last food intake. No food will be allowed for at least 3 hours after dosing.
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACT plus PQ (Rescue medication)
Description: Subjects with relapse during the 180 day follow up period will be given an ACT plus PQ 0.5 mg/kg for 14 days as rescue medication.
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT plus PQ (Rescue medication)
Description: Subjects with relapse during the 180 day follow up period will be given an ACT plus PQ 0.5 mg/kg for 14 days as rescue medication.
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT plus PQ (Rescue medication)
Description: Subjects with relapse during the 180 day follow up period will be given an ACT plus PQ 0.5 mg/kg for 14 days as rescue medication.
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PQ (End of study treatment)
Description: Subjects who do not relapse during the study will receive PQ 0.5mg/kg for 14 days at the end of the study.
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PQ (End of study treatment)
Description: Subjects who do not relapse during the study will receive PQ 0.5mg/kg for 14 days at the end of the study.
Study NCT02802501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ (End of study treatment)
Description: Subjects who do not relapse during the study will receive PQ 0.5mg/kg for 14 days at the end of the study.
Study NCT02032160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix B IM injection - 20ug
Description: Engerix B IM injection - 20ug At 0, 1 and 6 months
Study NCT02032160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fendrix IM injection - 20ug
Description: Fendrix IM injection - 20ug At 0, 1 and 6 months
Study NCT04839029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar En bloc TURBT
Description: patients subjected to Bipolar resection of bladder tumor by Collins loop
Study NCT04839029 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar En bloc TURBT
Description: patients subjected to Monopolar resection of bladder tumor by Collins loop (hot Knife)
Study NCT01191840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Duration
Study NCT01191840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Duration
Study NCT01910623 — intervention group
Intervention type: OTHER
Intervention: Health Related Quality of Life (HRQOL) measures
Study NCT00751764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Study NCT03073564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endurance test for upper limbs
Description: Subjects will initially perform maximal incremental cardiopulmnar test of upper limbs to assess the suggestion of dynamic hyperinflation (DH). After that, it will be randomized, for those who presented DH, to perform the endurance test with and without the use of positive expiratory pressure mask.
Study NCT03073564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional test
Description: The 6-min pegboard and ring test (6PBRT) will be performed under usual breathing and during application of the EPAP mask. In this condition will be evaluated the presence of dynamic hyperinflation, perception of effort and dipnea, in addition to exercise capacity.
Study NCT00672854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid, 20% Intravenous Emulsion
Description: It is made up of 20% Soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection
Study NCT00160771 — intervention group
Intervention type: BEHAVIORAL
Intervention: Joint Motion Analysis
Description: Joint motion will be recorded for analysis.
Study NCT00208949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
Study NCT00208949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: GM-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
Study NCT01760603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ISFF
Description: Ischia spinous fascia fixation surgery was performed on patient with pelvic organ prolapse.
Study NCT01669109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Study NCT03108365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axiostat
Description: Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Axiostat® stops moderate to severe bleeding due to cuts, abrasions, lacerations, venous/arterial punctures and more. Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area.
Study NCT03108365 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cotton Gauze
Description: Size: 1 x 1 cm
Study NCT02346201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Two 5mg methylphenidate over-encapsulated drug taken twice a day for 6 months (total of 20 mg methylphenidate per day), and psychosocial intervention
Study NCT02346201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention
Study NCT03420066 — intervention group
Intervention type: OTHER
Intervention: Retrospective data collection
Description: Retrospective collection of data recorded as standard of care for patients that were implanted with the Nexus device as part of Compassionate Use duly authorized according to country specific regulations.
Study NCT03381248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooled Radiofrequency
Description: Delivery of energy to ablate sensory nerves via cooled radiofrequency probe.
Study NCT03381248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid Injection
Description: Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain.
Study NCT03381248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crossover from Hyaluronic Acid Injection to Cooled Radiofrequency
Description: Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain. After 6 months, qualifying subjects in this group will have the option to crossover to receive cooled radiofrequency treatment.
Study NCT03516747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre operative parathyroid hormone level measurement
Description: At the clinic, the participants will undergo ultrasound examination with fine needle aspiration. The aspirated material will be sent for parathyroid hormone level measurement.
Study NCT03516747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre operative parathyroid cytology
Description: At the clinic, the participants will undergo neck ultrasound examination with fine needle aspiration. The aspirated material will be sent for cytology examination.
Study NCT03516747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: parathyroid hormone level measurement
Description: At surgery, after the pathologic gland is excised , the gland will be aspirated. The material will be sent for parathyroid hormone level measurement.
Study NCT03516747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: parathyroid cytology
Description: At surgery, after the pathologic gland is excised , it will be aspirated again for cytologic examination.
Study NCT01704664 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb)
Description: Early postoperative enteral nutrition with standard elementary diet (Peptisorb), will start 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition wil be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
Study NCT01704664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glutamine
Description: The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
Study NCT01704664 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oral diet enriched with arginine (Cubitan)
Description: Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they were administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
Study NCT01704664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative parenteral immunonutrition (Dipeptiven, Omegaven)
Description: Nutritional therapy of group IV will based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids were administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will start at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition was continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
Study NCT03401905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low frequency
Description: A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a low frequency TENS is applied, at 2 Hz frequency and 120 microseconds of pulse width.
Study NCT03401905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency
Description: A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a high frequency TENS is applied, at 12o Hz frequency and 200 microseconds of pulse width.
Study NCT00422656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Study NCT05432843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Patients receive for one week Pregabalin 75 mg and 7 weeks Pregabalin 150 mg
Study NCT05432843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive a treatment with placebo for 8 weeks
Study NCT03043378 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants complete three questionnaires at consultation visit.
Study NCT03262974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: PCR
Study NCT03262974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HPLC-UV
Description: HPLC-UV
Study NCT02465411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G4 or later generation
Description: Continuous glucose monitoring with DexCom G4 platina or later generations
Study NCT00914433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 1100
Description: 1 dose only increasing dose
Study NCT00604838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AL-SENSE Diagnostic Absorbent Panty liner
Description: worn for 12 hours
Study NCT00604838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AL-SENSE Diagnostic Absorbent Panty liner
Description: Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd worn for 12 hours
Study NCT03373526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: The Inspiratory Muscle Training will be perform using using the Power Breathe® device, during 20 minutes daily, five times a week. The protocol will be performed in the sitting position with an established load of 40% of maximal inspiratory pressure.
Study NCT03373526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training
Description: The aerobic physical training will be perform using a cycle ergometer, during 20 minutes daily, five times a week, with moderate intensity (50-70% of reserve heart rate).